Literature DB >> 17322885

A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis.

Chiea C Khor1, Stephen J Chapman, Fredrik O Vannberg, Aisling Dunne, Caroline Murphy, Edmund Y Ling, Angela J Frodsham, Andrew J Walley, Otto Kyrieleis, Amir Khan, Christophe Aucan, Shelley Segal, Catrin E Moore, Kyle Knox, Sarah J Campbell, Christian Lienhardt, Anthony Scott, Peter Aaby, Oumou Y Sow, Robert T Grignani, Jackson Sillah, Giorgio Sirugo, Nobert Peshu, Thomas N Williams, Kathryn Maitland, Robert J O Davies, Dominic P Kwiatkowski, Nicholas P Day, Djamel Yala, Derrick W Crook, Kevin Marsh, James A Berkley, Luke A J O'Neill, Adrian V S Hill.   

Abstract

Toll-like receptors (TLRs) and members of their signaling pathway are important in the initiation of the innate immune response to a wide variety of pathogens. The adaptor protein Mal (also known as TIRAP), encoded by TIRAP (MIM 606252), mediates downstream signaling of TLR2 and TLR4 (refs. 4-6). We report a case-control study of 6,106 individuals from the UK, Vietnam and several African countries with invasive pneumococcal disease, bacteremia, malaria and tuberculosis. We genotyped 33 SNPs, including rs8177374, which encodes a leucine substitution at Ser180 of Mal. We found that heterozygous carriage of this variant associated independently with all four infectious diseases in the different study populations. Combining the study groups, we found substantial support for a protective effect of S180L heterozygosity against these infectious diseases (N = 6,106; overall P = 9.6 x 10(-8)). We found that the Mal S180L variant attenuated TLR2 signal transduction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322885      PMCID: PMC2660299          DOI: 10.1038/ng1976

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  28 in total

Review 1.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

2.  Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor.

Authors:  D R Cundell; N P Gerard; C Gerard; I Idanpaan-Heikkila; E I Tuomanen
Journal:  Nature       Date:  1995-10-05       Impact factor: 49.962

3.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

Authors:  M Carrington; G W Nelson; M P Martin; T Kissner; D Vlahov; J J Goedert; R Kaslow; S Buchbinder; K Hoots; S J O'Brien
Journal:  Science       Date:  1999-03-12       Impact factor: 47.728

4.  Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88.

Authors:  Aisling Dunne; Mikael Ejdeback; Phumzile L Ludidi; Luke A J O'Neill; Nicholas J Gay
Journal:  J Biol Chem       Date:  2003-07-29       Impact factor: 5.157

5.  The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.

Authors:  Tiffany Horng; Gregory M Barton; Richard A Flavell; Ruslan Medzhitov
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

6.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

7.  Balancing selection at the prion protein gene consistent with prehistoric kurulike epidemics.

Authors:  Simon Mead; Michael P H Stumpf; Jerome Whitfield; Jonathan A Beck; Mark Poulter; Tracy Campbell; James B Uphill; David Goldstein; Michael Alpers; Elizabeth M C Fisher; John Collinge
Journal:  Science       Date:  2003-04-10       Impact factor: 47.728

8.  Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection.

Authors:  Richard Malley; Philipp Henneke; Sarah C Morse; Michael J Cieslewicz; Marc Lipsitch; Claudette M Thompson; Evelyn Kurt-Jones; James C Paton; Michael R Wessels; Douglas T Golenbock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-04       Impact factor: 11.205

9.  Pyogenic bacterial infections in humans with IRAK-4 deficiency.

Authors:  Capucine Picard; Anne Puel; Marion Bonnet; Cheng-Lung Ku; Jacinta Bustamante; Kun Yang; Claire Soudais; Stéphanie Dupuis; Jacqueline Feinberg; Claire Fieschi; Carole Elbim; Remi Hitchcock; David Lammas; Graham Davies; Abdulaziz Al-Ghonaium; Hassan Al-Rayes; Sulaiman Al-Jumaah; Sami Al-Hajjar; Ibrahim Zaid Al-Mohsen; Husn H Frayha; Rajivi Rucker; Thomas R Hawn; Alan Aderem; Haysam Tufenkeji; Soichi Haraguchi; Noorbibi K Day; Robert A Good; Marie-Anne Gougerot-Pocidalo; Adrian Ozinsky; Jean-Laurent Casanova
Journal:  Science       Date:  2003-03-13       Impact factor: 47.728

10.  FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis.

Authors:  Menna R Clatworthy; Kenneth G C Smith
Journal:  J Exp Med       Date:  2004-02-23       Impact factor: 14.307

View more
  174 in total

1.  Interleukin-1β regulates CXCL8 release and influences disease outcome in response to Streptococcus pneumoniae, defining intercellular cooperation between pulmonary epithelial cells and macrophages.

Authors:  Helen M Marriott; Kate A Gascoyne; Ravi Gowda; Ian Geary; Martin J H Nicklin; Francesco Iannelli; Gianni Pozzi; Timothy J Mitchell; Moira K B Whyte; Ian Sabroe; David H Dockrell
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

2.  Does M. tuberculosis genomic diversity explain disease diversity?

Authors:  Mireilla Coscolla; Sebastien Gagneux
Journal:  Drug Discov Today Dis Mech       Date:  2010

3.  Mannose-binding lectin and Toll-like receptor polymorphisms and Chagas disease in Chile.

Authors:  Thomas Weitzel; Inés Zulantay; Ina Danquah; Lutz Hamann; Ralf R Schumann; Werner Apt; Frank P Mockenhaupt
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

4.  Toll-like receptor 1 polymorphisms increase susceptibility to candidemia.

Authors:  Theo S Plantinga; Melissa D Johnson; William K Scott; Esther van de Vosse; Digna R Velez Edwards; P Brian Smith; Barbara D Alexander; John C Yang; Dennis Kremer; Gregory M Laird; Marije Oosting; Leo A B Joosten; Jos W M van der Meer; Jaap T van Dissel; Thomas J Walsh; John R Perfect; Bart Jan Kullberg; Mihai G Netea
Journal:  J Infect Dis       Date:  2012-02-01       Impact factor: 5.226

Review 5.  Pneumococci: immunology of the innate host response.

Authors:  Gavin K Paterson; Carlos J Orihuela
Journal:  Respirology       Date:  2010-07-20       Impact factor: 6.424

6.  Role of S180L polymorphism in etiology of malaria caused by Plasmodium falciparum in a small group of Pakistani population.

Authors:  Syed Kashif Nawaz; Bisma Ahmed; Najma Arshad; Asima Rani; Hamadia Rasool; Muhammad Arshad
Journal:  Bosn J Basic Med Sci       Date:  2015-08-19       Impact factor: 3.363

7.  Genetic predisposition of variants in TLR2 and its co-receptors to severe malaria in Odisha, India.

Authors:  Subhendu Panigrahi; Avishek Kar; Sagnika Tripathy; Manoj K Mohapatra; Gunanidhi Dhangadamajhi
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

8.  Toll-like receptor polymorphisms and tuberculosis susceptibility: A comprehensive meta-analysis.

Authors:  Qin Sun; Qing Zhang; He-Ping Xiao; Chong Bai
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

9.  The course of gastric cancer following surgery is associated with genetic variations of the interleukin-1 receptor antagonist and interleukin-1β.

Authors:  Anke H van der Ploeg; Oliver Kumpf; Evelyn Seelow; Luis C Berrocal Almanza; Peter M Schlag; Ralf R Schumann; Lutz Hamann
Journal:  Gastric Cancer       Date:  2014-02-21       Impact factor: 7.370

10.  Malaria primes the innate immune response due to interferon-gamma induced enhancement of toll-like receptor expression and function.

Authors:  Bernardo S Franklin; Peggy Parroche; Marco Antonio Ataíde; Fanny Lauw; Catherine Ropert; Rosane B de Oliveira; Dhelio Pereira; Mauro Shugiro Tada; Paulo Nogueira; Luiz Hildebrando Pereira da Silva; Harry Bjorkbacka; Douglas T Golenbock; Ricardo T Gazzinelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.